Mepitel Film showed no difference versus StrataXRT for moist desquamation in breast cancer patients receiving adjuvant radiation therapy.
This systematic review and meta-analysis pooled data from randomized controlled trials involving 120 breast cancer patients receiving adjuvant radiation therapy. The study compared the use of Mepitel Film against StrataXRT to assess skin toxicity outcomes during post-mastectomy radiotherapy. Methodological limitations included small and potentially underpowered sample sizes, as well as variations in radiation fractionation schedules and radiotherapy techniques.
Regarding primary outcomes, the incidence of moist desquamation was similar between groups, with a relative risk of 1.03 (95% CI 0.52-2.04; P = 0.93). Specifically, 21.7% of patients in the StrataXRT group experienced moist desquamation compared to 20.0% in the Mepitel Film group. For Grade 2 or 3 radiation dermatitis, Mepitel Film demonstrated a significant reduction in incidence with a relative risk of 1.34 (95% CI 1.10-1.64; P = 0.004).
Safety and tolerability data were mixed. While no serious adverse events or discontinuations were reported, itchiness was noted as an adverse event. The incidence of itchiness was 10.8% with Mepitel Film versus 5.0% with StrataXRT, representing a trend toward higher incidence with Mepitel Film (P = 0.11). Patient preference data regarding the dressings were conflicting. Given the underlying methodological limitations and small sample size, these findings should be interpreted with caution before altering clinical practice.